MaxCyte, Inc. MaxCyte announces leadership appointments
October 13 2020 - 2:00AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
13 October 2020
MaxCyte Bolsters Leadership Team with Promotion of Brad
Calvin
to Chief Commercial Officer and New Key VP Appointments
Gaithersburg, Maryland - 13 October 2020: MaxCyte, Inc. (LSE:
MXCT, MXCL), a global cell-based therapies and life sciences
company, announces today a senior leadership promotion and
appointments for two key vice president roles.
Brad Calvin has been promoted to Chief Commercial Officer. In
his previous role as MaxCyte Executive Vice President, Global
Commercial Operations, Mr. Calvin was responsible for leading the
Company's sales, marketing and business development functions to
define product strategy, deliver new products and drive growth of
its drug discovery and cell therapy businesses. In addition, Sarah
Haecker Meeks, PhD, has joined the Company as Vice President,
Business Development, and Steve Nardi has joined as Vice President,
Manufacturing and Engineering Operations.
MaxCyte's President & CEO Doug Doerfler, said: "Brad's
promotion is well-earned and important for MaxCyte's future growth.
Since joining MaxCyte in 2017, he has forged pivotal relationships
with leading cell therapy and gene editing companies, leading to
multiple successful clinical and commercial agreements. He led the
successful launch of our proprietary ExPERT(TM) platform, which
enables MaxCyte to support the needs of our biopharma partners as
they work to improve outcomes for patients with increasingly
sophisticated cell-based therapies."
Mr. Calvin noted, "It's exciting to think that the work we do at
MaxCyte to design products to meet the needs of our customers helps
to bring us closer to breakthrough therapies for patients. I look
forward to building on this work and to continuing to support
evolving customer needs as MaxCyte's Chief Commercial Officer."
As Mr. Calvin begins his expanded role, Dr. Meeks and Mr. Nardi
are important additions to MaxCyte's leadership team. Before
joining MaxCyte, Dr. Meeks served as Vice President of Business
Development at Synpromics (now part of AskBio) where she
established a leading market position for the company, including
partnerships with leading gene therapy companies, and led broad
technology education and adoption initiatives. Prior to her work at
Synpromics, she was the Chief Scientific Officer at Adjuvant
Partners. She received a PhD in biochemistry, molecular biology and
biophysics, with a minor in bioethics, from the University of
Minnesota and completed postdoctoral work in the University of
Pennsylvania Gene Therapy Program and Center for Technology
Transfer with continued education in the Wharton MBA Program.
Mr. Nardi previously served as Vice President of Worldwide
Manufacturing at Iradimed Corporation where he introduced lean
manufacturing principles, and improved transparency, cost control
and accountability. Prior to his work at Iradimed, Mr. Nardi was
the Senior Manager of Manufacturing and Engineering at Haemonetics
Corporation. He received both a BS in Science, Engineering and
Technology and an MS in Technology Commercialization at
Northeastern University.
MaxCyte's President & CEO, Doug Doerfler, added: "We are
extremely pleased to welcome both Sarah and Steve to MaxCyte.
Sarah's extensive corporate development experience across the gene
and cell therapy sector and Steve's broad knowledge of innovative
manufacturing strategy and R&D will help MaxCyte continue to
extend the reach of its next-generation cell engineering
technologies. These technologies hold great promise for global drug
development companies working on breakthrough therapies for
patients."
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFFAITLFLII
(END) Dow Jones Newswires
October 13, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024